O principal controle do ciclo celular de mamíferos, que é dividido em G0/G1/S/G2/M, ocorre na transição G0→G1→S. Nesta tese mostramos que a proteína ciclina D1 desempenha um papel fundamental nos circuitos de transdução de sinais que regulam a transição G0→G1→S na linhagem Y-1 de células adrenocorticais de camundongo. Esta conclusão não é surpreendente, uma vez que, ao longo dos últimos anos, muitos laboratórios contribuíram para estabelecer a noção de que a atividade das diversas formas do complexo ciclina/CDK é essencial para a transição G0→G1→S, e também para outras etapas do ciclo celular. Em células Y-1, FGF-2 induz tardiamente (5-6h) a expressão do gene e da proteína ciclina D 1, através de um processo dependente de síntese de proteínas. Peptídeos hipofisários não identificados e vasopressina bloqueiam a indução de ciclina DI, antagonizando FGF-2. Por este mecanismo, vasopressina exerce um efeito anti-mitótico, bloqueando a transição G0→G1→S promovida por FGF-2. ACTH, que também exibe um forte efeito anti-mitótico sobre FGF-2 não afeta a indução de ciclina D1. A transfecção dupla de uma forma induzível de c-Myc (MycER) e constitutiva do cDNA de ciclina D1, em presença de ACTH mimetiza a ação mitogênica de FGF-2 em células Y-1 no estado G0. Estes resultados mostram que, em células adrenocorticais, c-Fos, c-Jun, c-Myc e ciclina D1 agem de forma independente e complementar, sendo necessários para a transição G0→G1→S do ciclo celular. / The main control of mammalian cell cycle, which is divided in G0/G1/S/G2/M, occurs in G0→G1→S transition. In this work we show that cyclin D1 protein plays a key role in signal transduction circuits underlying the G0→G1→S transition of mouse Y-1 adrenocortical cell line. This conclusion is not surprising, once in the last years, many laboratories have contributed to establish the notion that the activity of the distinct forms of cyclin/CDK complexes is essential for the G0→G1→S transition, and also for other phases transition of cell cycle. In Y-1 cells, FGF-2 causes a delayed (5-6h) induction of cyclin D1 gene and protein, through a process dependent on protein synthesis. Hypophisary peptides, not identified, as well as vasopressin, block cyclin D1 induction, antagonizing FGF-2. By this mechanism, vasopressin exert an antimitotic effect, blocking G0→G1→S transition promoted by FGF-2. ACTH, which also exhibit a strong anti-mitotic effect upon FGF-2, does not affect cyclin D1 induction. Double transfection of inducible c-Myc (MycER) and constitutive cyclin D1 cDNA, in the presence of ACTH, mimics the mitogenic action of FGF-2 in G0 Y-1 cells. Altogether, these results show that, in adrenocortical cells, c-Fos, c-Jun, c-Myc and cyclin D1 act in an independent and complementary manner, being necessary for the G0→G1→S transition of cell cycle.

The DDT metabolite 3-methylsulfonyl-DDE (3-MeSO2-DDE) is bioactivated by cytochrome P450 11B1 (CYP11B1) in the adrenal cortex of mice and forms irreversibly bound protein adducts, reduces glucocorticoid secretion, and induces cell death selectively in cortisol-producing adrenocortical cells. 3-MeSO2-DDE has therefore been proposed as a lead compound for an improved adrenocortical carcinoma (ACC) therapy. The aims of this thesis were to (1) develop in vitro test systems based on murine and human adrenocortical cell lines and to (2) investigate the mechanisms behind 3-MeSO2-DDE toxicity in adrenocortical cells. The cytotoxic and endocrine-modulating effects of 3-MeSO2-DDE were compared to those of o,p′-DDD (mitotane), the current ACC therapy, and to those of several structurally analogous compounds in both murine and human cell lines. 3-MeSO2-DDE bioactivation and cytotoxicity proceeded in a similar manner in the murine adrenocortical Y-1 cell line as in mice in vivo. The effects were highly structure-specific. Moreover, 3-MeSO2-DDE formed irreversibly bound protein adducts and caused cell death also in the human H295R cell line, and was slightly more cytotoxic than o,p′-DDD. However, 3-MeSO2-DDE toxicity in human cells was not affected by the CYP11B1 inhibitor etomidate, suggesting that bioactivation in human cells is performed by additional/other enzyme(s) than CYP11B1. 3-MeSO2-DDE generated biphasic responses in cortisol and aldosterone secretion and in expression levels of the steroidogenic genes CYP11B1, CYP11B2, and StAR. Such hormesis-like responses were not seen for o,p′-DDD or the precursor DDT metabolite p,p′-DDE. In addition, the two o,p′-DDD enantiomers (R)-(+)-o,p′-DDD and (S)-(-)-o,p′-DDD exhibited slight differences in cytotoxic and endocrine-modulating activity in H295R cells. In conclusion, this thesis  provides  extended  knowledge  on  the  mechanisms  of  action  of 3-MeSO2-DDE and points out important differences in effects between murine and human cells. Lead optimisation studies of 3-MeSO2-DDE using the herein presented in vitro test systems are ongoing.

The DDT metabolite 3-methylsulphonyl-DDE (3-MeSO2-DDE) induces cell death specifically in the adrenal cortex of mice after a cytochrome P45011B1 (CYP11B1)-catalysed bioactivation. This substance is not only an environmental pollutant, but also a suggested lead compound for an improved chemotherapy of adrenocortical carcinoma (ACC). The aim of the thesis was to further investigate this compound in terms of kinetics, cell death mechanisms and species differences. The pharmacokinetics of 3-MeSO2-DDE and the current drug for ACC, o,p’-DDD, was studied during 6 months following a single dose in minipigs. The elimination was slower for 3-MeSO2-DDE than for o,p’-DDD, indicated by a lower clearance and longer t½ in plasma and subcutaneous fat. Both substances remained in fat tissue during the whole study period. Unlike o,p’-DDD, 3-MeSO2-DDE was retained also in liver. The adequacy of the murine adrenocortical cell line Y-1 was evaluated for studies of adrenotoxic compounds. The Y-1 cells proved to be an appropriate test system for future mechanism studies, since CYP-catalysed irreversible binding, inhibited corticosterone production induced by 3-MeSO2-DDE and o,p’-DDD were successfully demonstrated. Cell death of 3-MeSO2-DDE in the mouse adrenal cortex was implied to be necrotic. Early apoptotic signalling (i.e. up-regulation of caspase-9) was observed, although it seemed to be interrupted by ATP-depletion and anti-apoptotic actions by heat shock protein 70, resulting in lack of activation of caspase-3. Using cultured adrenal tissue slices, two not previously studied species were examined ex vivo regarding adrenal binding of 3-MeSO2-[14C]DDE. Binding was found in the hamster adrenal cortex and in assumed cortical cells in the medulla, while the guinea pig adrenal was devoid of binding. This emphasises the species specificity in bioactivation of 3-MeSO2-DDE. The thesis forms a basis for further investigations in the human adrenocortical cell line H295R and provides new knowledge of importance for toxicological risk assessment of 3-MeSO2-DDE.

As more and more wireless applications/services emerge in the market, the already heavily crowded radio spectrum becomes much scarcer. Meanwhile, however,as it is reported in the recent literature, there is a large amount of radio spectrum that is under-utilized. This motivates the concept of cognitive radio wireless networks that allow the unlicensed secondary-users (SUs) to dynamically use the vacant radio spectrum which is not being used by the licensed primary-users (PUs). In this dissertation, we investigate protocol design for both the synchronous and asynchronous cognitive radio networks with emphasis on the medium access control (MAC) layer. We propose various spectrum sharing schemes, opportunistic packet scheduling schemes, and spectrum sensing schemes in the MAC and physical (PHY) layers for different types of cognitive radio networks, allowing the SUs to opportunistically utilize the licensed spectrum while confining the level of interference to the range the PUs can tolerate. First, we propose the cross-layer based multi-channel MAC protocol, which integrates the cooperative spectrum sensing at PHY layer and the interweave-based spectrum access at MAC layer, for the synchronous cognitive radio networks. Second, we propose the channel-hopping based single-transceiver MAC protocol for the hardware-constrained synchronous cognitive radio networks, under which the SUs can identify and exploit the vacant channels by dynamically switching across the licensed channels with their distinct channel-hopping sequences. Third, we propose the opportunistic multi-channel MAC protocol with the two-threshold sequential spectrum sensing algorithm for asynchronous cognitive radio networks. Fourth, by combining the interweave and underlay spectrum sharing modes, we propose the adaptive spectrum sharing scheme for code division multiple access (CDMA) based cognitive MAC in the uplink communications over the asynchronous cognitive radio networks, where the PUs may have different types of channel usage patterns. Finally, we develop a packet scheduling scheme for the PU MAC protocol in the context of time division multiple access (TDMA)-based cognitive radio wireless networks, which is designed to operate friendly towards the SUs in terms of the vacant-channel probability. We also develop various analytical models, including the Markov chain models, M=GY =1 queuing models, cross-layer optimization models, etc., to rigorously analyze the performance of our proposed MAC protocols in terms of aggregate throughput, access delay, and packet drop rate for both the saturation network case and non-saturation network case. In addition, we conducted extensive simulations to validate our analytical models and evaluate our proposed MAC protocols/schemes. Both the numerical and simulation results show that our proposed MAC protocols/schemes can significantly improve the spectrum utilization efficiency of wireless networks.